in vivo electrophysiology for pain drug discovery
- E-Phys specializes in electrophysiological studies in anesthetized rodents for pain drug discovery.
- E-Phys’ expertise is based on many years of experience of the founder and collaborators within drug discovery research in CROs and large pharmaceutical companies.
- E-Phys’ activity started in summer 2012, with the installation of its own dedicated in vivo electrophysiology platform within the medical and pharmaceutical school in the Université Clermont-Auvergne, Clermont-Ferrand, France.
In vivo electrophysiology: a mandatory complement to pain behavioural assays.
- Electrophysiology allows the measurement of neurophysiological activity at the origin of the experience of pain, eliminating behavioural bias/interpretation.
- Evoked responses of pain pathways to highly noxious stimuli can be measured, which is not possible in behavioural assays. All forms of stimuli can be used.
- The neural activity at the origin of “spontaneous” pain can be assessed, regardless of the existence of a corresponding behavioural expression.
- Experiments, which are performed in anesthetized animals, allow any invasive procedures required to determine mechanism of action and efficacy of drug candidates.
Founder & CEO
Senior scientist with more than 10 years’ experience in academic research and in the drug discovery industry. Possessing 2 independent Master’s Degrees, in Biochemistry and Neuroscience, together with a PhD in Neuroscience with a strong emphasis on pharmacology and molecular biology, he switched to pain drug development during his work at Pfizer Global Research and Development (in Sandwich, UK, from 2006 to 2011) where he developed in vivo electrophysiology models in mice for different discovery programs.
Head of Business Development
After completing a Master’s in Applied Electronics, she specialised in logistics in the Plastics Industry for 15 years. In 2003, Anne Secondo joined Médecin sans Frontières (Doctors without Borders), where she demonstrated further her managerial and organisational talents during a number of humanitarian crises in Africa and Asia. She also works as a consultant for a diverse group of other companies.
Wesley D. Miner
Senior Scientific Advisor
Wesley D. Miner has over 35 years of experience in drug discovery in the pharmaceutical industry (GlaxoSmithKline; Pfizer) and contract research (Inveresk Research International). Following studying physiology at the University of Edinburgh Medical School, he discovered the antiemetic activity of 5-HT3 antagonists (granisetron, tropisetron, ondansetron) and was also a key member of the biology team that discovered darifenacin (M3 selective antimuscarinic). During his time with Pfizer he spent 10 years investigating mechanisms involved in visceral pain.